Agenda
Optimizing Current Management of Hemophilia A
Mitigating Complications and Overcoming Barriers in Patients Receiving Factor Replacement Therapy
Future Directions: Evolving Role of Nonfactor Replacement Therapies
Final Thoughts and Audience Question and Answer Session
Faculty
Program Director
Miguel A. Escobar, MD
Professor of Medicine and Pediatrics
Department of Hematology
University of Texas Health Science Center
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas
Faculty
Michael Callaghan, MD
Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Children's Hospital of Michigan
Detroit, Michigan
Faculty
Rebecca Kruse-Jarres, MD, MPH
Director, Bloodworks Northwest/Washington Center for Bleeding Disorders
Associate Professor, Medicine and Pediatrics
University of Washington
Seattle, WA
Goal Statement
The goal of this activity is to improve the knowledge and competence of learners in using novel curative and noncurative therapeutic options for patients with hemophilia A.
Target Audience
This program is intended for hematologists and other clinicians involved in the management of patients with hemophilia A.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Implement individualized hemophilia A management strategies that optimize adherence, outcomes, and utilization of resources
- Analyze recent data on the efficacy, safety, and tolerability of emerging nonfactor replacement strategies for the management of hemophilia A with and without inhibitors
- Discuss progress in the management of hemophilia A with factor-based interventions, including use of extended half-life agents
- Mitigate and manage complications and comorbidities in patients receiving prophylaxis for hemophilia A
- Develop approaches for individualizing therapy based on patient-specific and disease-specific characteristics
- Evaluate available data for novel agents and treatment strategies and determine patients with hemophilia A who may be eligible for a clinical trial
Accreditation
Joint Accreditation Statement
In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
Credit Designation
CCO designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.